Insulet Corp
Chiusa
SettoreSettore sanitario
145.05 1.14
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
141.4
Massimo
146.11
Entrata | -11M 91M |
|---|---|
Vendite | -22M 762M |
P/E Media del settore | 34.612 49.712 |
EPS | 1.3 |
Margine di Profitto | 11.96 |
Dipendenti | 5,400 |
EBITDA | -23M 154M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +59.8% upside |
Utili prossimi | 6 ago 2026 |
|---|
Capitalizzazione di Mercato | -1.6B 10B |
|---|---|
Apertura precedente | 143.91 |
Chiusura precedente | 145.05 |
Notizie sul Sentiment di mercato
By Acuity
61%
39%
269 / 342 Classifica in Healthcare
Insulet Corp Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.